{"id":297097,"date":"2023-11-15T20:26:44","date_gmt":"2023-11-16T01:26:44","guid":{"rendered":"https:\/\/platohealth.ai\/comparing-sales-of-cd20xcd3-bispecifics-for-lymphoma\/"},"modified":"2023-11-16T09:30:42","modified_gmt":"2023-11-16T14:30:42","slug":"comparing-sales-of-cd20xcd3-bispecifics-for-lymphoma","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/comparing-sales-of-cd20xcd3-bispecifics-for-lymphoma\/","title":{"rendered":"Comparing\u00a0sales of CD20xCD3 bispecifics for lymphoma","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

DATA GRAPHICS | Data Byte<\/p>\n

\n
\n
\n

Epkinly sales take off in its second quarter on the market<\/h2>\n

By <\/span>Gunjan Ohri, Data Content Analyst<\/span><\/span>\n<\/p>\n

November 16, 2023 1:26 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

In its second quarter on the market, sales of Genmab and AbbVie\u2019s subcutaneous CD20xCD3 bispecific, Epkinly, grew nearly fourfold, surpassing sales of competing intravenous CD20xCD3 bispecifics from Roche<\/a> and Biogen.<\/p>\n

FDA approved Epkinly epcoritamab, developed by partners Genmab A\/S<\/a> (CSE:GMAB; NASDAQ:GMAB) and AbbVie Inc.<\/a> (NYSE:ABBV), on May 19 to treat diffuse large B-cell lymphoma (DLBCL) after two or more lines of treatment. The approval was the first of two this year for a CD20xCD3 bispecific in the indication, followed by Columvi glofitamab from Roche (SIX:ROG; OTCQX:RHHBY) on June <\/span>15…<\/p>\n